We need your support to keep TheyWorkForYou running and make sure people across the UK can continue to hold their elected representatives to account.

Donate to our crowdfunder

Health: Cancer Drugs Fund

House of Lords written question – answered on 18th July 2013.

Alert me about debates like this

Photo of Lord Turnberg Lord Turnberg Labour

To ask Her Majesty’s Government, further to the Written Answer by Earl Howe on 25 June (WA 110), whether their commitment to protect patients receiving treatment through the Cancer Drugs Fund extends (1) to new patients requiring cancer treatment arising after the end of the Fund, and (2) to existing patients who have recurrent but not ongoing need for treatment previously received through the Fund.

Photo of Earl Howe Earl Howe The Parliamentary Under-Secretary of State for Health

In the context of developing new pricing arrangements for branded medicines, we are exploring ways in which new patients can continue to benefit from innovative cancer drugs at a cost that represents value to the National Health Service.

We understand from NHS England that if a patient is receiving a drug through the Cancer Drugs Fund, they can continue to receive that drug as long as their oncologist considers they have a clinical need and are benefiting from the treatment.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.